How should I transition a patient from apixaban (Eliquis) to therapeutic enoxaparin (low‑molecular‑weight heparin)?

Transitioning from Apixaban to Therapeutic Enoxaparin

Stop apixaban and start therapeutic enoxaparin at the time of the next scheduled apixaban dose without any bridging or overlap period. 1

Transition Protocol

The FDA-approved prescribing information for apixaban (Eliquis) provides explicit guidance for this transition 1:

• Discontinue apixaban completely
• Begin enoxaparin at the usual time when the next dose of apixaban would have been taken
• No bridging anticoagulation is required during this transition
• No overlap period is necessary

Therapeutic Enoxaparin Dosing

Once you initiate enoxaparin, use standard therapeutic dosing based on the clinical indication 2, 3, 4:

For VTE treatment (DVT/PE):

• 1 mg/kg subcutaneously every 12 hours (preferred for most patients)
• Alternative: 1.5 mg/kg subcutaneously once daily

For cancer-associated VTE:

• 1 mg/kg twice daily or 1.5 mg/kg once daily 2, 4

For acute coronary syndromes:

• 1 mg/kg subcutaneously every 12 hours 3
• Initial IV loading dose of 30 mg may be used in selected patients
• Reduce to 1 mg/kg once daily if creatinine clearance <30 mL/min 3

Critical Timing Considerations

The transition timing is straightforward because:

1. Apixaban has a half-life of approximately 12 hours 5, meaning anticoagulant effect diminishes predictably
2. Enoxaparin provides immediate anticoagulation after subcutaneous administration with peak anti-Xa activity in 3-5 hours
3. The FDA label explicitly states to begin the new anticoagulant at the time of the next scheduled apixaban dose 1

Important Caveats and Pitfalls

Renal function assessment is mandatory:

• Calculate creatinine clearance before initiating enoxaparin 3, 5
• If CrCl <30 mL/min: reduce enoxaparin to 1 mg/kg once daily 3
• If CrCl <15 mL/min: consider unfractionated heparin instead 5

Body weight considerations:

• Standard weight-based dosing applies for BMI <40 kg/m² 4
• For BMI ≥40 kg/m²: consider 0.8 mg/kg every 12 hours after the first month 4

Avoid switching back and forth:

• Once you transition to enoxaparin, avoid switching back to apixaban or to unfractionated heparin unnecessarily, as this increases bleeding risk 6

Monitoring is generally not required:

• Routine anti-factor Xa monitoring is unnecessary for most patients 3
• Consider monitoring only in extreme body weights, renal impairment, pregnancy, or if bleeding/thrombosis occurs despite therapy 7

Clinical context matters:

• This transition is typically done when oral anticoagulation becomes temporarily unsuitable (e.g., pre-procedure, acute illness, inability to take oral medications, significant renal dysfunction precluding DOAC use) 2
• If the patient requires urgent anticoagulation reversal or has active bleeding, this is a different scenario requiring specific reversal strategies 8